Login / Signup

Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis.

Alessandro MiolaMichele FornaroPaul A TaylorMarco Solmi
Published in: Human psychopharmacology (2021)
Melatonin/ramelteon augmentation may be beneficial for non-anthropometric metabolic syndrome components in patients treated with antipsychotics.
Keyphrases
  • metabolic syndrome
  • insulin resistance
  • uric acid
  • body composition
  • cardiovascular risk factors
  • cardiovascular disease
  • adipose tissue
  • type diabetes